PRZOOM - /newswire/ -
Monrovia, CA, United States, 2011/03/21 - Elham Behshad, Ph.D., Principal Investigator at Incyte to give a presentation on a collaboration with Novartis titled “Phosphorylation State and Compound Selectivity; c-Met HTS as Case Study” at GTCbio’s 6th Protein Kinases Conference.
Elham Behshad, Ph.D., to give a presentation on a collaboration with Novartis titled “Phosphorylation State and Compound Selectivity; c-Met HTS as Case Study” at GTCbio’s 6th Protein Kinases in Drug Discovery Conference on May 26-27, 2011 in Boston, MA.
Dr. Behshad will discuss a collaboration project with Novartis as Phase I trials begin for a c-MET inhibitor named INCB28060 that could successfully overcome drug resistance in lung, kidney and gastric cancers.
This meeting will offer you an intimate forum to engage in discourse with industry leaders from major pharmaceutical companies, biotech companies as well as top researchers from academia and government regarding the complex activities of kinases and cutting-edge solutions to the challenges associated with kinase drug development.
Notable presenters include Keith T. Flaherty, M.D., Principal Investigator and Director of Developmental Therapeutics at Massachusetts General Hospital Cancer Center; Nathanael S. Gray, Ph.D., Principal Investigator of Biological Chemistry and Molecular Pharmacology at Dana Farber Cancer Institute; William C. Shakespeare, Ph.D., Vice President, Drug Discovery at ARIAD Pharmaceuticals; and Marcie A. Glicksman, Ph.D., Co-Director, Laboratory for Drug Discovery at Harvard Neurodiscovery Center.
Also presenting at the Protein Kinase Conference are scientists from prestigious organizations including Abbott, Amgen, Ansaris, ArQule, Avila Tx, Biogen Idec, Broad Institute, Dana Farber, DE Shaw Research, Genentech, Harvard Neurodiscovery Center, Mass Gen Hospital, Millennium, Merck, Novartis, OSI Pharma, Pfizer, and other leaders in the kinase industry.
For more information, please visit gtcbio.com/.